We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Low-Cost Blood Test May Enable Screening for Increased Bleeding Risk After Injury

By LabMedica International staff writers
Posted on 11 Oct 2015
From a proof-of-concept, pre-validation study, researchers have concluded that the admission hematocrit (AH) would likely provide a reliable predictor of increased bleeding risk in pediatric trauma patients.

From their retrospective review of approximately 1,340 trauma patients, ages 0 to 17 years, researchers from the Trauma Program at Children's Hospital Los Angeles (CHLA; Los Angeles, CA, USA) have suggested that an AH could be widely implemented to identify patients who may need intervention and thus improve the course and outcome of their trauma resuscitation.

Adult trauma studies have shown that a drop in hematocrit (test for percentage of the volume of whole blood that is made up of red blood cells) can occur immediately after injury – predicting ongoing occult blood loss. More...
To date, the use of hematocrit in triaging bleeding pediatric trauma patients had not been investigated. In examining medical records of all patients who presented to CHLA’s level-1 pediatric trauma center between 2005 and 2013, the researchers found that an AH of 35-or-less was able to identify children requiring intervention (blood transfusion, angioembolization, or operation) for bleeding, up to 67 hours after arrival.

The results showed a significant difference in AH between patients who subsequently required a transfusion and those who did not. The cutoff figure of 35-or-less had a 94% sensitivity, 77% specificity, and 99.9% negative predictive value, indicating that use of this cutoff provides a reliable screening tool.

Unintentional injury from trauma is the leading cause of death in children over one year of age. Clinical assessment of young children can be far more challenging than adults, identifying their injuries (especially intra-abdominal) and assessing blood loss in children often requires additional resources and expense. "A quick and cost-effective measure, such as AH, to identify pediatric patients who are at a high risk for bleeding could provide a critical improvement in optimizing care for children, while reducing costs," said principal investigator Christopher P. Gayer, MD, PhD, FAAP, FACS, of Trauma Attending, Division of Pediatric Surgery, CHLA.

"AH can be done rapidly in the trauma bay, is relatively inexpensive, causes minimal harm, and can aid in critical decision-making and rapid identification of occult bleeding. Our results show that a hematocrit level of less than 35% on admission predicts a greater likelihood for the need of transfusion in pediatric blunt trauma patients," said first author Jamie Golden, MD, research fellow, CHLA.

The physicians noted that while a doctor's concern in the face of clinical signs of hemorrhagic shock should always take priority over lab data, a repeat hematocrit can be quickly performed if clinically indicated. They added that their study results, conducted retrospectively at a single site, require validation in a prospective, multicenter study.

The study, by Golden J et al, was published in the October, 2015, issue of the Journal of Trauma and Acute Care Surgery.

Related Links:

Children's Hospital Los Angeles



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.